RhumbLine Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
Other funds holding PHAT
6CM
RhumbLine Advisers's PHAT Position: Q3 2026 in Review
RhumbLine Advisers increased its Phathom Pharmaceuticals (PHAT) stake by 13% in Q3 2026, buying an estimated $72.9K and bringing the position to 68,084 shares worth $497K. The position accounts for ﹤0.01% of the portfolio, ranked #2732.
RhumbLine Advisers first reported a position in PHAT in Q4 2019 and has held it in 28 quarters since. The position peaked at $920K in Q3 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.
- RhumbLine Advisers held 68,084 shares of Phathom Pharmaceuticals worth $497K as of Q3 2026.
- RhumbLine Advisers bought 7,738 Phathom Pharmaceuticals shares in Q3 2026, an estimated $72.9K.
- Phathom Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2732 holding.
- RhumbLine Advisers first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 28 quarters since.
- RhumbLine Advisers's Phathom Pharmaceuticals position peaked at $920K in Q3 2024.
- 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.